SCHEMBL27363818

SCHEMBL27363818

Cc1ccc(N2CCN(CC3CCN(C)CC3)CC2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
LMNA P02545 2/20 0.40
POLB P06746 1/20 0.39
MAPT P10636 6/20 0.38
GFER P55789 1/20 0.38
KDM2B Q8NHM5 1/20 0.38
CACNA2D1 P54289 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNB1 Q02641 1/20 0.38
CACNA1C Q13936 1/20 0.38
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27367505 0.85 MAPK1 (0.43) MAPK1SMN1; SMN2DRD2DRD4LMNA
SCHEMBL27363822 0.85 MAPK1 (0.40) MAPK1DRD2DRD4MAPTCACNA2D1
SCHEMBL2610122 0.79 SMN1; SMN2 (0.47) MAPK1SMN1; SMN2LMNAPOLBMAPT
SCHEMBL19003699 0.79 SMN1; SMN2 (0.47) MAPK1SMN1; SMN2LMNAPOLBMAPT
SCHEMBL27372185 0.79 SMN1; SMN2 (0.47) MAPK1SMN1; SMN2LMNAPOLBMAPT
SCHEMBL27362860 0.79 MAPT (0.50) SMN1; SMN2DRD2POLBMAPTGFER
SCHEMBL27364621 0.79 MAPT (0.47) SMN1; SMN2DRD2POLBMAPTCACNA2D1
SCHEMBL10132281 0.78 MAPK1 (0.51) MAPK1SMN1; SMN2DRD2DRD4LMNA
SCHEMBL27365978 0.76 MAPK1 (0.42) MAPK1SMN1; SMN2DRD2DRD4MAPT
SCHEMBL24834707 0.76 MAPT (0.47) DRD2MAPTGFERCACNA2D1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024054591-A1 RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-03-14 WO disclosed